supplementary material - thorax

Supplementary material Thorax

doi: 10.1136/thoraxjnl-2019-213744–84.:82 75 2019;Thorax, et al. Janson C

/ 10

PCF Certification Summary

Footprint Results

In the table below you will find the carbon footprint results of your SKUs. For full details of all of your

product carbon footprint results, please refer to your certification letter (CERT-12506).

Product Category: Asthma and COPD Treatment

Product

Stock

Keeping

Unit

Geographic

Area

Net kgCO2e

not rounded

per pack

Net

kgCO2e

Rounded

per pack

Net kgCO2e

Rounded

per

actuation

Net

kgCO2e

Rounded

per dose

Net

kgCO2e

Rounded

per day

Ellipta

Relvar Ellipta

92/22 mcg

United

Kingdom

0.776 0.80 0.026 0.026 0.026

Anoro Ellipta

55/22 mcg0.784 0.80 0.026 0.026 0.026

Arnuity

Ellipta 100

mcg*

0.771 0.75 0.026 0.026 0.026

Incruse

Ellipta 55

mcg

0.739 0.75 0.024 0.024 0.024

Diskus

Ventolin

Accuhaler

200 mcg

0.583 0.60 0.010 0.010 As needed

Seretide

Accuhaler

50/500 mcg

0.898 0.90 0.015 0.015 0.030

Flixotide

Accuhaler

500 mcg

0.833 0.85 0.014 0.014 0.028

Serevent

Accuhaler0.732 0.75 0.012 0.012 0.024

MDI

Ventolin

Evohaler 100

mcg

28.262 28.00 0.141 0.283 As needed

Seretide

Evohaler

25/250 mcg

19.485 19.00 0.162 0.325 0.650

Flixotide

Evohaler 250

mcg

19.277 19.00 0.158 0.317 0.650

Serevent

Evohaler 25

mcg

19.223 19.00 0.158 0.317 0.650

* Arnuity Ellipta 100 mcg is currently not sold in the UK. The footprint is based on using the same assumptions for UK distribution and end

of life as the other two Ellipta products.



/ 10


Data Collection

As with the previous certification round, Richard and his team collected all the required primary data

for all sites owned and operated by GSK to calculate the footprints

The data from the production of the APIs was primary data taken directly from the Jurong

Factory for the 2016 year. Energy at these sites was allocated based on firstly the area(s)

of the site that produced APIs for respiratory products, and secondly the physical volumes

of the different types of APIs produced.

The data for the production of the final products was primary data taken directly from the

Ware, Evreux and Aranda production sites for the 2016 year. Energy at these sites was

allocated based on firstly the area(s) of the site that produced respiratory products, and

secondly the physical volumes of the differences types of respiratory products produced.

Unlike the previous certification round, primary data was not collected from GSK’s device manufacturers in the UK, France and Germany. This was accepted on the basis that although

primary data from suppliers were not available this time, the devices are highly regulated and the

specification of the devices have not changed since 2013. Thus, previous results are still

considered as accurate. Primary data from GSK still account for at least 10% of the footprint of

all products, meeting the requirements of PAS2050:2011. To summarise, the footprint results

from the following processes were taken directly from previous certified GSK footprints:

• The manufacturing of Ellipta devices in Germany.

• The manufacturing of actuators for MDI devices in Spain.

• The manufacturing of MDI cans for MDI devices in Germany.

• The manufacturing of Diskus devices/components in Germany.

• The manufacturing of Diskus devices/components in France.

• The manufacturing of Diskus devices/components in UK.

As with the previous certification, the following data was collected for the distribution, use and end

of life stages:

The retail stage (i.e. pharmacy storage) was considered to be immaterial to these

footprints since all 12 products are stored at ambient temperature. Therefore retail

emissions were not calculated.

The distribution and end of life stages were calculated using the Footprint Expert

calculators which were populated with good quality secondary data on transport

distances (i.e. google maps) and product weights.

The use phase was calculated using the known propellant release of each actuation (for

MDI products) and the instructions for use of the products in their patient pamphlets.



/ 10


Preferential application of primary emissions factors were used where available. Where no primary

emissions factor was available, conversion factors (emissions factors) were taken from the Footprint

Expert database (version 4.3) which were provided to you with your Footprint Expert Toolkit licence.

Where no relevant emissions factor was available in the Footprint ExpertTM database, emissions

factors were taken from the GlaxoSmithKline emissions factor database or a proxy emissions factor

was applied.

Communications

You have achieved full certification against all the required standards for use the

Carbon Trust’s ‘Carbon Measured’ label. As a valued customer we have provided a free

licence for use of the label. Please get in touch to discuss how you could use this label

and promote the work you have done on product carbon footprinting. We would be

more than happy to work with you on options for joint marketing and PR in association

with this certification.

Recommended Future Actions

Due to the importance of device manufacturing to Ellipta and Diskus products, we recommend that

GSK re-engages with the device component suppliers to collect accurate, recent primary data so

that any recent improvements and changes at supplier level are taken into account, and so that GSK

has the correct data to monitor your product carbon footprint over time.

For consistency in future footprinting and maintain high levels of data quality, GSK should look

to develop a data collection and data quality manual covering all sites that GSK owns and operates

(for internal use). This would document the exact processes of obtaining primary data at

Jurong, Montrose, Evreux and Ware, specify the exact reports to be generated and the

allocation methodologies and calculations to be applied to split energy at the API or SKU level.

This manual would be used to guide any future verification services, including a potential site visit to

review its use and the knowledge of staff using it. This will be beneficial in addressing any

questions around the processes used and where data is gathered for the next audit.

In general, incremental improvements can be made to the way energy data is allocated between

APIs and between the final products. It was noted in this certification that at times, the initial

percentage allocation of energy between respiratory and non-respiratory products was evidenced

by an email from the site manager, instead of calculated outputs from raw data. Going

forward, clear documentation should be kept for all the percentages calculated.

Within respiratory products/APIs, the allocation of energy by API or final product was conducted by

product volume. Going forward, GSK should look to collect more primary data on differences in

energy requirements between different outputs, especially for APIs. A more granular analysis can

be made to look at, for example, whether certain APIs require more electricity, steam, or natural gas

than other APIs. It is appreciated by the Carbon Trust this is a long-term improvement however this

should be prioritised for future footprinting.



supplementary material - thorax

Documents